List view / Grid view
21 September 2015 | By Roche
Roche announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015...
21 September 2015 | By Victoria White
Merck plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the US, EU and Canada in 2015...
21 September 2015 | By Victoria White
The FDA approval is based on the results of three 3-week controlled trials in adults with bipolar I disorder and three 6-week placebo-controlled trials in adults with schizophrenia...
21 September 2015 | By Victoria White
Following news that a British man had been producing the Polio virus for 30 years, experts say high immunisation coverage should keep us covered, but changes to immunisation strategies may be required...
21 September 2015 | By Victoria White
The EC has granted Marketing Authorisation for Intuniv for the treatment of ADHD in children and adolescents for whom stimulants are not suitable...
17 September 2015 | By Black Swan
Market Publishers and Black Swan Analysis signed a partnership agreement for quality market research promotion on the Internet...
17 September 2015 | By Victoria White
The DUAL V trial evaluated the efficacy and safety of Xultophy compared to insulin glargine U100 in adults with type 2 diabetes...
17 September 2015 | By Victoria White
BioInject will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics...
17 September 2015 | By Andor Technology
The most advanced and powerful software solution for analysis, data management and presentation of comet assay samples...
17 September 2015 | By Andor
Andor Komet software characterises ‘Comets’ to detect Cancer...
Results from Inovio’s Phase 2b trial with VGX-3100 in treating women with high grade cervical neoplasia have been published.
17 September 2015 | By Radwag
Advanced Radwag solutions for traceability of measurement...
17 September 2015 | By Victoria White
The value of the global therapeutics market for benign prostatic hyperplasia will rise from $2 billion in 2014 to approximately $4.9 billion by 2024...
17 September 2015 | By Victoria White
LT-02 is a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis...
17 September 2015 | By Victoria White
Under the terms of the acquisition agreement, Amgen will pay $300 million in cash at closing and up to $1.25 billion in additional payments...
